Axial Spondyloarthritis Management Market is expected to reach US$ 7.3 Billion, & expected to grow with a 5.1% CAGR during 2023 to 2033 | Future Market Insights, Inc. NEWARK, Del, March 31, 2023 (GLOBE NEWSWIRE) -- During the forecast period 2023 to 2033, the Axial Spondyloarthritis management market is expected to grow at a value of 5.1% CAGR, according to...

Axial Spondyloarthritis Pipeline: Drug Pipeline, Regulatory Events and Clinical Trials in the Spotlight| Insights by DelveInsight Los Angeles, June 17, 2021 (GLOBE NEWSWIRE) -- Axial Spondyloarthritis Pipeline: Drug Pipeline, Regulatory Events and Clinical Trials in the Spotlight| Insights by DelveInsight The report offers...

American College of Rheumatology Encourages Safe Adoption of Biosimilars During FDA Public Hearing on CT-P13, a Proposed Biosimilar for Infliximab (Remicade) ATLANTA, Feb. 10, 2016 (GLOBE NEWSWIRE) -- During a public meeting held Tuesday by the Food and Drug Administration (FDA)'s Arthritis Advisory Committee to review the license application of CT-P13,...